Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Please find enclosed a Press Release on "Dr.

Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S.

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Dr. Reddy's Laboratories and Senores Pharmaceuticals,

launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Hyderabad, India and Princeton, NJ, USA. May

24, 2022 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries

together referred to as "Dr. Reddy's") and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac

Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S.

market approved by the U.S. Food and Drug Administration (USFDA).

Ketorolac Tromethamine Tablets USP, 10 mg,

is a nonsteroidal anti-inflammatory drug ("NSAID") indicated for the short-term (up to 5 days in adults) management

of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous

or intramuscular dosing of ketorolac tromethamine, if necessary.

"We are pleased to partner with Dr. Reddy's

Laboratories for the commercial launch of Ketorolac Tromethamine Tablets in the U.S. market," states Dhananjay Barot, Director,

Senores Pharmaceuticals, Inc.

"Our constant dedication has contributed

to expanding our product portfolio, and today we are a significant and reliable supplier of this product," states Swapnil

Shah, Managing Director, Senores Group.

"We are excited about this launch, and

pleased to partner with Senores to create affordable access to this product and expand our portfolio in the US market," says

Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories.

The Toradol Tablets, 10 mg brand and generic

had U.S. sales of approximately $16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA*.

Dr. Reddy's Ketorolac Tromethamine Tablets

USP, 10 mg, are available in bottle count sizes of 100.

Please click here to see the full prescribing

information and approved indication, along with boxed warning for Dr. Reddy's Ketorolac Tromethamine Tablets USP, 10 mg.

Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory

drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires

analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary.

The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days.

Ketorolac tromethamine tablets are not indicated for use in pediatric

patients and they are NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine tablets

beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse

CARDIOVASCULAR THOMBOTIC EVENTS

Ketorolac tromethamine is CONTRAINDICATED as prophylactic analgesic

before any major surgery.

RISK DURING LABOR AND DELIVERY

CONCOMITANT USE WITH NSAIDs

Important Safety Information: Ketorolac Tromethamine Tablets,

What Important Information Should I Know About Ketorolac Tromethamine

Who Should Not Use Ketorolac Tromethamine Tablets, 10 mg?

What Should I Tell My Healthcare Ketorolac

Tromethamine Tablets, 10 mg?

Before taking Ketorolac Tromethamine

Tablets, tell your doctor if you:

What Are the Possible Side Effects of Ketorolac Tromethamine

These are not all of the possible side effects

of Ketorolac Tromethamine Tablets, 10 mg. Call your doctor for medical advice about side effects. For more information, ask your

doctor or pharmacist. You are encouraged to report negative side effects of prescription drugs. To report suspected side effects,

call Dr. Reddy's Laboratories Medical Information Call Center at 1-888-DRL-DRUG (1-888-375-3784) or via email to medinfo@drreddys.com

or contact the US FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/safety/medwatch. Please refer

to the Ketorolac Tromethamine Tablets, 10 mg Package Inserts for full Prescribing Information and Instructions for Use

Indication and Usage for Ketorolac Tromethamine

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed

to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services

including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas

of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates

in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,

log on to: www.drreddys.com

About Senores Pharmaceuticals, Inc.

Senores Pharmaceuticals, based in Atlanta,

Georgia is one of the fastest-growing pharmaceutical companies in the U.S. market. Currently, the company has more than 15 products

commercially launched or filed with the USFDA. For more information, visit www.senorespharma.com

Disclaimer: This press release may include statements of future

expectations and other forward-looking statements that are based on the management's current views and assumptions and involve

known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those

expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",

"will", "should", "expects", "plans", "intends", "anticipates", "believes",

"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking

statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,

(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates,

persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing

levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks

and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi)

the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic

downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19),

and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including

those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form

20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.